A recent single-arm, phase 3 study (RIDGELINE VX21-121-105)1 published in The Lancet Respiratory Medicine2 has shown positive results for vanzacaftor–tezacaftor–deutivacaftor in treating paediatric cystic fibrosis (CF) patients, demonstrating improvements in lung function, sweat chloride levels and quality of life. This trial focused on children aged 6 to 11 years, a group often excluded from studies involving adults or older children, as well as key ages for CF treatment.

As 2024 comes to a close and as the new Patient Advisory Board & Advocacy Manager at EUFOREA, I have the privilege to reflect on the achievements and milestones of EUFOREA this year. With my background as a pharmacist and scientific ...

As 2024 draws to a close, we’re celebrating a fantastic year of content.

A recent phase 2 trial published in The Lancet Respiratory Medicine has demonstrated that benralizumab, a monoclonal antibody targeting interleukin-5 receptor-α, can significantly reduce treatment failure in eosinophilic exacerbations of asthma and COPD.

The International Primary Care Respiratory Group (IPCRG), is proud to host the 8th IPCRG Scientific Meeting in Brașov, Romania, on Friday 11 and Saturday 12 April 2025. This event, in partnership with the RespiRO team and the Transilvania University of Brașov promises to bring together researchers, innovators, and industry leaders to advance respiratory care in primary health settings.

The International Primary Care Respiratory Group (IPCRG) has initiated a global social movement to bring meaningful change in asthma management. The driving idea behind this initiative is a recognition that, while the current approach may feel sufficient to many, it falls short of optimal care. The IPCRG network sees clear evidence of avoidable harm and unnecessary costs in the current asthma management framework, which continue to impact lives and wellbeing.1 To counteract this, IPCRG's "Asthma Right Care" aims to inspire a shift towards better care practices by reducing both overuse and underuse of effective treatments. This means moving beyond episodic symptom relief and acute responses to establish a chronic care model that adheres to international or national asthma guidelines, prioritizing the appropriate use of anti-inflammatory inhaled medications.

COP29, currently underway in Baku, is bringing together global leaders to address the multifaceted issues of climate change, with healthcare firmly on the agenda. In a speech delivered by the WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, he emphasized the critical link between climate change and human health, reinforcing that the climate crisis is, at its core, a health crisis. The escalating climate emergency is no longer a distant threat; it is already affecting human lives, particularly those of vulnerable groups like women and children.

Although there is limited evidence on the link between interstitial lung disease (ILD) and malnutrition, malnourished patients tend to have shorter survival rates, regardless of disease severity. A late-breaking abstract presented at ERS 2024 titled “Dietetic intervention in malnourished patients with interstitial lung disease (ILD): a pilot trial” investigated whether dietitian involvement could provide meaningful benefits to these patients, potentially laying the groundwork for further research and future clinical guidelines.

A new study in the European Respiratory Journal reveals that early-life BMI trajectories significantly influence lung function outcomes in young adulthood, with abnormal BMI patterns linked to poorer respiratory health.